An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

This is a first-in survivor pilot study with the goal of establishing preliminary evidence of
efficacy, safety, and tolerability of two senolytic regimens to reduce markers of cellular
senescence (primary outcome: p16^INK4a) and improve frailty (primary outcome: walking speed)
in adult survivors of childhood cancer. If successful, this pilot would provide the
preliminary evidence needed for a phase 2, randomized, placebo-controlled trial to establish
efficacy.

Primary Objective

- The primary aim of this proposal is to test the efficacy of two, short duration
senolytic regimens: 1) combination of Dasatinib plus Quercetin and 2) Fisetin alone, to
improve walking speed and decrease senescent cell abundance in blood (p16^INKA):

- Primary endpoints of this trial will be change in walking speed and senescent cell
abundance in blood (p16^INK4A) determined at baseline and again at 60 days, within an
individual arm. Extended follow up at 150 days will assess the permanence of change
after completion of the trial. Secondary endpoints of this trial will be effect of
intervention on additional measures of frailty (beyond walking speed; Fried criteria)
and on other cell senescence markers, markers of inflammation, insulin resistance, bone
resorption, and cognitive function.

Secondary Objectives

The secondary aim is to test the safety and tolerability of two different senolytic
therapies.

Exploratory Objectives

- To compare the efficacy of the two senolytic regimens in improving walking speed and
decreasing senescent cell abundance

- To evaluate the longitudinal pattern in measures of frailty.

Intervention

Dasatinib plus Quercetin, Fisetin

Condition

Frailty, Childhood Cancer

Investigators

Gregory T. Armstrong, MD, MSCE

See list of participating sites